Back in April, I wrote about MDRevolution and its effort to build a next-generation health practice that combines cardiology, nutrition science and genetics with new mobile health technology. Now, the San Diego-based company is trying to take its program national.
On Wednesday, at the Digital Health Summit in New York, the company announced the launch of RevUp, a subscription-based online service for employers, health systems and physician groups. It aggregates a wide range of patient information – from fitness trackers and other devices to genetic and other health data – and provides each patient with a customized health plan. Through the service, patients can log their progress and receive personalized feedback and coaching, and it lets employers and physicians monitor progress as well.
Since 2012, MDRevolution has run a San Diego facility that blends the clinical mindset of a doctor’s office with the research focus of a lab. It says it has helped about 250 patients improve their heart health and lose weight through a program that includes genetic tests (that look for fitness- and nutrition-related predispositions), metabolic assessments (that determine a patients’ resting heart rate and other health indicators) and mobile devices (like Fitbits and other fitness trackers) that monitor patient activity and programs.
Along the way, the company has collected mounds of data about patient progress that the company’s founder and CEO, Samir Damani, said has led to new insights on how diet and exercise can improve health. And it’s those insights that inform the algorithms that enable RevUp to generate customized health programs.
As we’ve said before, corporate wellness is becoming an increasingly competitive space, as more companies – like Keas and ShapeUp, for example – pitch employers with digital services meant to lower health costs and boost employee productivity. Damani, a cardiologist, believes RevUp’s data-driven programs give it an edge over other companies in the space.
The company, which partners with Qualcomm, 23andMe and Pathway Genomics, has raised $1.6 million in angel funding and counts Sharp Healthcare and Pharmatek among its corporate clients.